If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. This page covers who may need closer monitoring based on FAERS data, building on a long tradition of pharmacovigilance that links real-world evidence to safer prescribing. Here, we break down diagnosis essentials and recommended follow-up.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates clinical, pharmacological, and risk-related evidence to inform patients and legal professionals in North Carolina about the medical realities and settlement considerations associated with Tysabri-induced PML. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that results from reactivation of the JC virus in immunocompromised individuals. Clinically, PML presents with subacute neurological deficits that vary depending on the location of brain lesions. Common symptoms include progressive weakness on one side of the body, visual disturbances such as hemianopia, cognitive decline, ataxia, and speech difficulties. Diagnosis typically relies on brain MRI showing multifocal white matter lesions without mass effect, combined with detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. In some cases, brain biopsy may be required. The disease usually leads to death or severe disability, as noted in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrin, blocking adhesion molecules on leukocytes and thereby reducing their migration into the central nervous system. This mechanism is effective in controlling inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus. The drug's pharmacology directly increases the risk of PML by limiting the ability of the immune system to control latent JC virus infection. The prescribing information explicitly states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The mechanistic pathway involves JC virus reactivation in the setting of reduced central nervous system immune surveillance due to Tysabri's blockade of lymphocyte trafficking. The virus then infects oligodendrocytes, leading to lytic destruction of myelin-producing cells and progressive neurological damage.
The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The drug carries a boxed warning that clearly states the increased risk of PML and the need for monitoring. Healthcare professionals are instructed to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and prescribers were adequately informed about the magnitude of risk, particularly in relation to individual risk factors and the potential for delayed diagnosis. Settlement-related considerations for affected patients in North Carolina involve several factors. The timeline between Tysabri exposure and documented harm is critical. PML can develop after varying durations of treatment, from a few months to several years. The prescribing information notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For legal purposes, establishing the date of first Tysabri infusion, the date of PML symptom onset, and the date of definitive diagnosis is essential. Medical records should document neurological examinations, MRI findings, and JC virus PCR results. Patients who develop PML may face catastrophic outcomes, including permanent disability or death. Settlement negotiations often consider the severity of neurological impairment, the need for lifelong care, lost earning capacity, and medical expenses. In North Carolina, state law may affect damage caps or liability standards, so consultation with a local attorney experienced in pharmaceutical injury cases is advisable. The restricted distribution program may also be relevant to claims about informed consent and whether the patient fully understood the risks before starting treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML) by blocking immune cell migration into the brain, reducing surveillance against JC virus. The prescribing information states that Tysabri increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.
Patients may pursue claims based on inadequate warnings or failure to monitor. Key evidence includes the boxed warning and TOUCH program requirements. Settlement considerations involve the timeline of exposure, severity of injury, and North Carolina state law. Consulting a local pharmaceutical injury attorney is recommended.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.